- Home
- CGO vs RPID Comparison
CGO vs RPID Comparison
Compare CGO & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- RPID
- Stock Information
- Founded
- CGO 2004
- RPID 2006
- Country
- CGO United States
- RPID United States
- Employees
- CGO N/A
- RPID N/A
- Industry
- CGO Investment Managers
- RPID Medical Specialities
- Sector
- CGO Finance
- RPID Health Care
- Exchange
- CGO Nasdaq
- RPID Nasdaq
- Market Cap
- CGO 119.4M
- RPID 106.5M
- IPO Year
- CGO N/A
- RPID 2021
- Fundamental
- Price
- CGO $12.21
- RPID $3.23
- Analyst Decision
- CGO
- RPID Strong Buy
- Analyst Count
- CGO 0
- RPID 2
- Target Price
- CGO N/A
- RPID $8.00
- AVG Volume (30 Days)
- CGO 34.7K
- RPID 70.7K
- Earning Date
- CGO 01-01-0001
- RPID 10-31-2025
- Dividend Yield
- CGO 9.25%
- RPID N/A
- EPS Growth
- CGO N/A
- RPID N/A
- EPS
- CGO N/A
- RPID N/A
- Revenue
- CGO N/A
- RPID $30,289,000.00
- Revenue This Year
- CGO N/A
- RPID $16.63
- Revenue Next Year
- CGO N/A
- RPID $21.98
- P/E Ratio
- CGO N/A
- RPID N/A
- Revenue Growth
- CGO N/A
- RPID 22.57
- 52 Week Low
- CGO $7.90
- RPID $0.83
- 52 Week High
- CGO $10.93
- RPID $4.50
- Technical
- Relative Strength Index (RSI)
- CGO 68.93
- RPID 60.49
- Support Level
- CGO $12.05
- RPID $2.93
- Resistance Level
- CGO $12.20
- RPID $3.52
- Average True Range (ATR)
- CGO 0.17
- RPID 0.23
- MACD
- CGO 0.04
- RPID 0.09
- Stochastic Oscillator
- CGO 93.33
- RPID 77.14
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.